Regeneron (REGN) misses earnings, revenue expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Regeneron Pharma (REGN) PT Lowered to $1,185 at RBC Capital
May 3, 2024 6:46 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,185.00 (from $1,189.00) while maintaining a Outperform rating.
The analyst comments "Overall, a reasonably solid quarter, with Eylea HD looking good, Eylea 2mg missing probably to a... More
Regeneron's blockbuster eye drug posts weaker sales due to inventory impact
May 2, 2024 6:39 AM EDT(Reuters) -U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for quarterly profit on Thursday, hurt by softer sales of its blockbuster eye drug Eylea due to reduction in wholesaler inventory.
Apart from an impact of about $40 million cut in inventory, Regeneron said changing market dynamics that resulted in lower volumes and lower selling price also hurt Eylea sales.
Total sales of the drug,... More
Regeneron (REGN) Misses Q1 EPS by 64c
May 2, 2024 6:36 AM EDTRegeneron (NASDAQ: REGN) reported Q1 EPS of $9.55, $0.64 worse than the analyst estimate of $10.19. Revenue for the quarter came in at $3.15 billion versus the consensus estimate of $3.22 billion.
For earnings history and earnings-related data on Regeneron (REGN) click here.
... More